Discontinued drugs in 2008: Oncology drugs

Expert Opinion on Investigational Drugs

Volumn 18, Issue 11, 2009, Pages 1581-1594

  Williams, Robert ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

1D09C3; 4 demethylpenclomedine; ARQ 171; AZD 4992; CNF 1010; DN 101; FCE 28068; FCE 28069; Folitixorin calcium; HuMy9 6 DM4; INNO 305; Mitumprotimut T; MLN 8054; N acetylcysteine; PD 0325901; Phosphomannopentaose sulfate; PI 166; SGX 523; Spisulosine; Symadex

Indexed keywords

1D09C3; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; 4 DEMETHYLPENCLOMEDINE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ANX 510; ARQ 171; AVE 9633; AZD 4992; CALCITRIOL; CLOMET; CNF 1010; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; ES 285; FCE 28068; FCE 28069; FLUOROURACIL; FOLITIXORIN CALCIUM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INNO 305; LILLY 3; MITUMPROTIMUT T; MLN 8237; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHOMANNOPENTAOSE SULFATE; PI 166; PI 88; SGX 523; SORAFENIB; SPISULOSINE; SYMADEX; TOZASERTIB LACTATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANOLIMUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADRENAL CANCER; B CELL LYMPHOMA; BIOTECHNOLOGY; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DATA BASE; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG WITHDRAWAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPERCALCEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGY; PANCREAS CANCER; PROSTATE CANCER; QT PROLONGATION; REVIEW; RHEUMATOID ARTHRITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG DESIGN; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS;

EID: 73849107464     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903151806     Document Type: Review

References (9)

1. Williams RJ. Discontinued drugs in 2006: oncology drugs. Expert Opin Investig Drugs 2008;17(3):269-283
2. Williams RJ. Discontinued drugs in 2007: oncology drugs. Expert Opin Investig Drugs 2008;17(12):1791-1816
3. Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates. Nat Rev Drug Discov 2009;8(1):15-16
4. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00147550?term= pd-0325901&rank=2
5. Force T, Kerkelä R. Cardiotoxicity of the new cancer therapeutics - mechanisms of, and approaches to, the problem. Drug Discov Today 2008;13(17/18):778-784
6. Scrip news. 2009 Feb 27th:6-7
7. Cancer drug. 2009 Dec 17th:1
8. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-715
9. The Pharmaprojects database. In Informa, UK 2009